[go: up one dir, main page]

TR200100569T2 - Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler - Google Patents

Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler

Info

Publication number
TR200100569T2
TR200100569T2 TR2001/00569T TR200100569T TR200100569T2 TR 200100569 T2 TR200100569 T2 TR 200100569T2 TR 2001/00569 T TR2001/00569 T TR 2001/00569T TR 200100569 T TR200100569 T TR 200100569T TR 200100569 T2 TR200100569 T2 TR 200100569T2
Authority
TR
Turkey
Prior art keywords
composition
oral
mucosa
agents
safe
Prior art date
Application number
TR2001/00569T
Other languages
English (en)
Inventor
Joseph Dobrozsi Douglas
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of TR200100569T2 publication Critical patent/TR200100569T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

Mevcut bulus, bilesimin agirligina göre yaklasik %2 ila yaklasik %50 titanyum dioksit koloidal parçaciklari ve mide-bagirsak maddeleri, analjezikler, dekonjestanlar, ekspektoranlar, antitüsifler, antihistaminler, bronsodilatörler, topikal anestetikler, algi maddeleri, oral bakim maddeleri, çesitli solunum maddeleri, ve bunlarin karisimindan olusan gruptan seçilen bir farmasötik aktif maddenin güvenli ve etkili miktarini içeren bir oral veya oral mukozada tutunan sulu sivi farmasötik bilesim ile ilgilidir; ki burada bilesim yaklasik 48 saat sonra ölçülen yaklasik 0.90'dan daha büyük bir çökme hacmi oranina sahiptir ve bilesimin tetiklenmis viskozite orani en az yaklasik 1.2'dir. Mevcut bulus ayrica, yukaridaki bilesimin güvenli ve etkili bir miktarinin uygulanmasi ile, beslenme kanali veya nasal mukozanin kaplanmasi, özellikle üst solunum sistemi enfeksiyonlari ve üst solunum sistemi doku tahrisi ve tahribinin önlenmesi ve tedavi edilmesi için bir yöntemle ilgilidir.
TR2001/00569T 1998-08-24 1999-08-24 Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler TR200100569T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9764698P 1998-08-24 1998-08-24

Publications (1)

Publication Number Publication Date
TR200100569T2 true TR200100569T2 (tr) 2001-07-23

Family

ID=22264456

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00569T TR200100569T2 (tr) 1998-08-24 1999-08-24 Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler

Country Status (18)

Country Link
US (2) US20020009478A1 (tr)
EP (1) EP1107732B1 (tr)
JP (1) JP2002523353A (tr)
KR (1) KR20010074834A (tr)
CN (1) CN1313754A (tr)
AT (1) ATE227978T1 (tr)
AU (1) AU753251B2 (tr)
BR (1) BR9913148A (tr)
CA (1) CA2338480C (tr)
CO (1) CO5140074A1 (tr)
DE (1) DE69904057T2 (tr)
DK (1) DK1107732T3 (tr)
ES (1) ES2185395T3 (tr)
HU (1) HUP0103217A2 (tr)
NO (1) NO20010830L (tr)
PE (1) PE20000863A1 (tr)
TR (1) TR200100569T2 (tr)
WO (1) WO2000010528A1 (tr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
US7544348B2 (en) * 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
US7547433B2 (en) * 2001-02-15 2009-06-16 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
ES2195757B1 (es) * 2001-12-28 2005-03-01 Laboratorios Calier, S.A. Procedimiento para combatir las infestaciones de las colmenas de abejas.
AU2003222990B2 (en) * 2002-05-02 2009-11-12 Cragmont Pharmaceuticals, Llc Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
HUE033319T2 (en) * 2002-06-28 2017-11-28 Civitas Therapeutics Inc Inhalation epinephrine
US6669929B1 (en) 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
US20050058672A1 (en) * 2003-09-14 2005-03-17 Bioderm Research Baby Care Skin Protectant Compositions for Diaper Rash
DE10332486A1 (de) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung akuter Schmerzen
US7482378B2 (en) * 2004-05-28 2009-01-27 Millenium Specialty Chemicals, Inc. Physiological cooling compositions
EP1768647B1 (en) * 2004-06-17 2012-08-08 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agent
PL2522365T3 (pl) 2004-11-24 2017-05-31 Meda Pharmaceuticals Inc. Kompozycje zawierające azelastynę i sposoby ich zastosowania
US20060216359A1 (en) * 2005-03-25 2006-09-28 Lowell Riegel Topical preparation for treating ulcerations on the inside of the month
TR200803299T1 (tr) * 2005-11-10 2008-11-21 Century Biologicals Private Limited Solunum yolu rahatsızlıklarını tedavi etmek için kullanılan dengeli bir formülasyon.
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
FR2900824A1 (fr) * 2006-05-10 2007-11-16 Prod Dentaires Pierre Rolland Pate destinee a arreter les saignements, ses utilisations, et seringue la contenant
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
CN101138541B (zh) * 2006-09-06 2010-10-06 上海医药工业研究院 氨来占诺局部成膜凝胶组合物及其应用
EP2064222B1 (en) 2007-04-02 2014-05-07 Theracos, Inc. Benzylic glycoside derivatives and methods of use
BRPI0815708B8 (pt) 2007-08-23 2021-05-25 Theracos Sub Llc composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
US20090123570A1 (en) * 2007-11-09 2009-05-14 Warner W Randolph Composition and method for treating sore throat
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
WO2009064458A2 (en) 2007-11-13 2009-05-22 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20090148530A1 (en) * 2007-12-08 2009-06-11 Jamie Koufman Method for prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
KR102340754B1 (ko) 2008-04-21 2021-12-16 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
RU2509773C2 (ru) 2008-07-15 2014-03-20 Теракос, Инк. Дейтерированные бензилбензольные производные и способы применения
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CA2731769C (en) 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
DK2328553T3 (da) 2008-08-20 2020-08-24 Univ California Corticosteroider til behandling af inflammatoriske sygdomme i mave-tarm-kanalen
DK2324002T3 (en) 2008-08-22 2016-12-19 Theracos Sub Llc Methods of making of sglt2 inhibitors
US7914828B2 (en) * 2008-10-17 2011-03-29 Levine Brian M Combination herbal product to benefit respiratory tract
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
CN103153994B (zh) 2010-05-24 2016-02-10 罗切斯特大学 双环杂芳基激酶抑制剂及使用方法
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US8361519B2 (en) 2010-11-18 2013-01-29 Aadvantics Pharmaceuticals, Inc. Combination herbal product to benefit respiratory tract in people exposed to smoke
DK2675893T3 (en) 2011-02-18 2019-04-15 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells into a myelinating cell fate
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
ES2740958T5 (en) 2012-02-27 2025-04-03 Elanco New Zealand Controlled release compositions and their methods of use
US20150133565A1 (en) * 2012-06-15 2015-05-14 University Of New Hampshire Sustained release hydrogel-based stimulant
US9636360B2 (en) * 2012-09-18 2017-05-02 pH Science Holdings, Inc Method and composition for treating gastro-esophageal disorders
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
US11135158B2 (en) 2014-05-26 2021-10-05 Michael Lee Martin Medicated hard candy product for treating esophageal inflammation and a method using the same
US9867779B2 (en) * 2015-03-26 2018-01-16 Patheon Softgels Inc. Liquisoft capsules
CN108699160A (zh) 2015-07-28 2018-10-23 奥德纳米有限公司 用于治疗耳部病况的TrkB或TrkC激动剂组合物和方法
RU2727205C2 (ru) * 2015-09-28 2020-07-21 Эвоник Оперейшнс Гмбх Противомикробные композиции для полости рта на основе диоксида кремния
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
SI3737233T1 (sl) 2018-01-09 2025-10-30 Dompé Farmaceutici S.P.A. Ušesne formulacije z rastnimi faktorji
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
PH12021552180A1 (en) * 2019-03-14 2022-08-31 Intramont Tech Inc Preparations for the prevention of illnesses acquired via the oral cavity and pharynx
TW202227104A (zh) 2020-09-08 2022-07-16 瑞士商艾爾塔米拉醫療有限公司 預防感染之組合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352752A (en) * 1963-07-25 1967-11-14 Tintex Corp Intestinal adsorbent compositions
US4042679A (en) * 1975-11-07 1977-08-16 Colgate-Palmolive Company Antibacterial oral composition
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US4988679A (en) * 1989-01-03 1991-01-29 Leonard Chavkin Liquid sustained release composition
US4980175A (en) * 1989-01-03 1990-12-25 Leonard Chavkin Liquid orally administrable compositions based on edible oils
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
FI913127A0 (fi) * 1989-10-31 1991-06-27 Watson Lab Vid slemhinnan haeftade stoedsystem foer frigoerande av ett terapeutiskt aemne.
JPH0639368B2 (ja) * 1990-02-28 1994-05-25 株式会社萩原技研 シリカゲルを母体とした抗菌性組生物
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO1996021432A1 (en) * 1995-01-11 1996-07-18 Cygnus, Inc. Delivery of active substances by way of mucosal surfaces of pharyngeal and esophageal regions
IT1275955B1 (it) * 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
US5589160A (en) * 1995-05-02 1996-12-31 The Procter & Gamble Company Dentifrice compositions
US5658553A (en) * 1995-05-02 1997-08-19 The Procter & Gamble Company Dentifrice compositions
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions

Also Published As

Publication number Publication date
KR20010074834A (ko) 2001-08-09
CO5140074A1 (es) 2002-03-22
DE69904057D1 (de) 2003-01-02
US20020009478A1 (en) 2002-01-24
US6638521B2 (en) 2003-10-28
WO2000010528A1 (en) 2000-03-02
ATE227978T1 (de) 2002-12-15
ES2185395T3 (es) 2003-04-16
PE20000863A1 (es) 2000-09-12
CA2338480C (en) 2004-10-05
AU5580899A (en) 2000-03-14
BR9913148A (pt) 2001-09-25
DE69904057T2 (de) 2003-08-21
US20020076421A1 (en) 2002-06-20
NO20010830D0 (no) 2001-02-19
NO20010830L (no) 2001-02-19
CA2338480A1 (en) 2000-03-02
EP1107732B1 (en) 2002-11-20
AU753251B2 (en) 2002-10-10
CN1313754A (zh) 2001-09-19
HUP0103217A2 (hu) 2001-12-28
DK1107732T3 (da) 2003-03-17
EP1107732A1 (en) 2001-06-20
JP2002523353A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
TR200100569T2 (tr) Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler
TR200100628T2 (tr) Mukozaya yapışan (muko-adhesif) oral sıvı bileşimler.
DE69518334D1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
FI944123A0 (fi) Farmaseuttiset inhalaatiokoostumukset
PT893992E (pt) Formas de dosagem oral de desintegracao rapida
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
HUP0000520A2 (hu) Új vizes gyógyszerkészítmények hajtógázmentes aeroszolokhoz
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
CA2277365A1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
NO952906L (no) Farmasöytisk formulering for behandling av nikotinavhengighet
FR2712807B1 (fr) Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
TR200100566T2 (tr) Mukozaya yapışan(muko-adhesif)oral sıvı bileşimler
WO2001012128A3 (en) Antibacterial agents for the treatment of acute mucosal infections